Drug
Cabotegravir
Cabotegravir: highest development phase Phase 3, developed by ViiV Healthcare. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- ViiV Healthcare
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cabotegravir (CAB) tablet NCT02951052 | Phase 3 | Infection, Human Immunodeficiency Virus |
Latest
No recent events.
Follow Cabotegravir on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.